Thursday, December 10, 2020

Registration and Check-In

Exhibits Open

Welcome and Introduction 
Program Chairs: Nelson N. Stone, MD, and Richard G. Stock, MD

SESSION I: Prostate Biopsy

TRUS Prostate Biopsy: Can We Continue?
Gerald L. Andriole, Jr., MD

Transperineal Prostate Biopsy: OR Procedure
Nelson N. Stone, MD

Transperineal Prostate Biopsy: Office Procedure
Michael A. Gorin, MD

Panel Discussion

Break

SESSION II: Radiation Protection Devices

Rectal Displacement Reduces Potential for Injury, Application for EBRT and Brachytherapy
Richard G. Stock, MD

SESSION III: Brachytherapy

How to Select an Isotope: I-125, Pd-103 or Cs-111
Peter F. Orio III, MD

Transperineal Mapping Biopsy Improves the Selection of Implant Alone or Combination Therapy in Intermediate Risk Patients
Vassilios Skouteris, MD

Tailoring Radiation Dose for Low- and Intermediate-Risk Prostate Cancer 
Richard G. Stock, MD

How to Combine Brachytherapy and External Beam Irradiation
Patrick W. McLaughlin, MD

Panel Discussion

Lunch Break

HANDS-ON TRAINING COURSE: Office and OR Transperineal Prostate Biopsy, MRI Fusion Biopsy, Radiotherapy Protection Device Insertion, and Advanced Brachytherapy Techniques

SESSION IV: Hands-On Training

Stations are 45 minutes (total of 3 hours for the 4 stations). There will be a 20 minute break after 2 sessions (at 3pm). Maximum of 10 attendees per station.

Transperineal Office Biopsy With and Without MRI Fusion
Matthew J. Allaway, DO and Michael A. Gorin, MD

Transperineal Mapping OR Biopsy
Nelson N. Stone, MD, and Vassilios Skouteris, MD

SpaceOar Placement
Richard G. Stock, MD

Brachytherapy Techniques
Peter F. Orio III, MD, and Patrick W. McLaughlin, MD

On Own

Friday, December 11, 2020

Exhibits Open

Industry Breakfast Symposium
Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer Treatment Landscape
Speaker: Edward Uchio, MD, FACS, CPI
Supported by Astellas Pharma US and Pfizer Oncology

Break and Visit Exhibits

SESSION I: New Approaches to Prostate Cancer Diagnosis

Moderator: Gerald L. Andriole, Jr., MD

Changing Environment of Prostate Cancer Detection
Gerald L. Andriole, Jr., MD

The Infinite Value of PSA Screening: An Objective Critique of USPSTF Policy
Patrick W. McLaughlin, MD

mpMRI: Should It Be the First Test?
Andre L. de Castro Abreu, MD

Panel Discussion

Transperineal Office Biopsy: Should It Replace TRUS? 
Michael A. Gorin, MD

Transperineal Mapping Biopsy: Different Techniques, Different Results
Nelson N. Stone, MD

Panel Discussion

Break and Visit Exhibits
Sponsored by Sun Pharma

Coordination of New Serum and Molecular Markers With Advanced Imaging and Biopsy Techniques
Gerald L. Andriole, Jr., MD

Comparison of Biopsy Techniques to Prostatectomy Specimens 
M. Scott Lucia, MD

When Should Prostate Biopsy Be Done After Radiotherapy? Implications for Management
Richard G. Stock, MD

Panel Discussion

Industry Lunch Symposium – TBD

Break and Visit Exhibits

SESSION II: Focal Therapy

Moderator: Nelson N. Stone, MD

What Can the Pathologist Teach Us About Focal Therapy
M. Scott Lucia, MD

How to Utilize MRI for Focal Therapy Planning
Andre L. de Castro Abreu, MD

Transperineal Mapping and Focal Therapy Planning
Nelson N. Stone, MD

Focal Cryoablation: State of the Art
Michael A. Gorin, MD

Panel Discussion

Break and Visit Exhibits

Can Brachytherapy Be Used for Focal Therapy?
Peter F. Orio III, MD

Active Surveillance or Focal Therapy for Gleason Grade Group 2?
Michael A. Gorin, MD

Dynamic Anatomy

Panel Discussion

25th Anniversary Welcome Reception 

Northern Sky Terrace

Saturday, December 12, 2020

Exhibits Open

Industry Breakfast Symposium
Treating Patients With Advanced Prostate Cancer: Metastatic and Non-Metastatic PC
Speaker: Matthew B. Rettig, MD
Supported by Janssen

Break and Visit Exhibits

SESSION III: Diagnosis and Treatment of Advanced Disease

Moderator: Richard G. Stock, MD

Pathologically Defining High-Risk Disease
M. Scott Lucia, MD

The Case for Robotic Prostatectomy in High-Grade Prostate Cancer: 3D Models
Ketan K. Badani, MD

Radioisotopes to Treat Bone Metastases
Steven E. Finkelstein, MD

Combination Radiation for High-Grade Prostate Cancer
Jason A. Efstathiou, MD, PhD

RLAP Combined With Intraoperative Brachytherapy in High-Risk Prostate Cancer
Ketan K. Badani, MD

SBRT/CyberKnife®– Should It Replace IMRT?
Seth R. Blacksburg, MD, MBA

Panel Discussion

Break and Visit Exhibits

Advanced Imaging to Define Extraprostatic Prostate Cancer
Richard G. Stock, MD

Androgen Deprivation Therapy and Radiotherapy: When and How Long
Raoul S. Concepcion, MD

The Advantage to SBRT in the Treatment of Oligometastatic Disease
Seth R. Blacksburg, MD, MBA

Adjuvant RT + ADT After Prostatectomy
Jason A. Efstathiou, MD, DPhil

Panel Discussion

Industry Lunch Symposium
YONSA® – An Innovative Micronized Abiraterone Acetate Formulation
Speaker: Raoul S. Concepcion, MD
Supported by Sun Pharma

Break and Visit Exhibits

SESSION IV: Systemic Therapy

Moderator: Raoul S. Concepcion, MD

Neoadjuvant and Adjuvant Systemic Therapy for High-Risk Localized Disease
William K. Oh, MD

Treatment of Hormone Sensitive Metastatic Prostate Cancer
Alan H. Bryce, MD

Sequencing in Men With mCRPC
William K. Oh, MD

Immunotherapy for Castrate-Resistant Prostate Cancer
Raoul S. Concepcion, MD

Germline and Somatic Mutations: Can It Change Therapy?
Alan H. Bryce, MD

Updates on Treatment of mCRPC: AR, Chemo, and Bone Targeted Treatments
William K. Oh, MD

Case Presentations
Steven E. Finkelstein, MD, and Patrick W. McLaughlin, MD

Panel Discussion

Adjourn